Quantcast
Last updated on April 19, 2014 at 5:20 EDT

VIVUS to Present at the BIO CEO and Investor Conference

February 4, 2010

MOUNTAIN VIEW, Calif., Feb. 4 /PRNewswire-FirstCall/ — VIVUS, Inc. (Nasdaq: VVUS) today announced that Dr. Charles Bowden, senior director, clinical development, will present an overview of the company at the 12th Annual BIO CEO and Investor Conference.

The VIVUS presentation will take place at the Waldorf Astoria Hotel in New York on Tuesday, February 9, 2010 at 10:30 a.m. ET. A live webcast and 30-day archive of the presentation will be available at http://ir.vivus.com or http://www.veracast.com/webcasts/bio/ceoinvestor2010/84112554.cfm.

About VIVUS

VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health. The company’s lead product in clinical development, Qnexa®, has completed phase 3 clinical trials for the treatment of obesity and an NDA was submitted to the FDA in December 2009. Qnexa is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a potentially best-in-class PDE5 inhibitor for the treatment of erectile dysfunction, and in phase 2 development of Luramist(TM) for the treatment of hypoactive sexual desire disorder (HSDD) in women. MUSE® (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS. For more information about the company, please visit www.vivus.com.


    CONTACT:
    --------

    VIVUS, Inc.             Investor Relations: The Trout Group
    Timothy E. Morris                           Brian Korb
    Chief Financial Officer                     646-378-2923
    650-934-5200

                            Media Relations:    Pure Communications, Inc.
                                                Dan Budwick
                                                973-271-6085

SOURCE VIVUS, Inc.


Source: newswire